Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
1.
PLoS One ; 18(5): e0285107, 2023.
Article in English | MEDLINE | ID: covidwho-20236780

ABSTRACT

The coronavirus disease 2019 (COVID-19) pandemic not only encouraged people to practice good hygiene but also caused behavioral inhibitions and resulted reduction in both endemic and imported infectious diseases. However, the changing patterns of vector-borne diseases under human mobility restrictions remain unclear. Hence, we aimed to investigate the impact of transborder and local mobility restrictions on vector-borne diseases through a descriptive epidemiological study. The analysis was conducted using data from the National Epidemiological Surveillance of Infectious Diseases system in Japan. We defined the pre-pandemic period as the period between the 1st week of 2016 to the 52nd week of 2019 and defined the pandemic period as from the 1st week of 2020 to the 52nd week of 2021, with the assumption that human mobility was limited throughout the pandemic period. This study addressed 24 diseases among notifiable vector borne diseases. Datasets were obtained from weekly reports from the National Epidemiological Surveillance of Infectious Diseases, and the incidence of each vector-borne disease was examined. Interrupted time series analysis was conducted on the epidemic curves for the two periods. Between the pre- and post-pandemic periods, the incidence of dengue fever and malaria significantly decreased, which may be related to limited human transboundary mobility (p = 0.003/0.002). The incidence of severe fever with thrombocytopenia syndrome, scrub typhus, and Japanese spotted fever did not show changes between the two periods or no association with human mobility. This study suggests that behavioral control may reduce the incidence of new mosquito-borne diseases from endemic areas but may not affect tick-borne disease epidemics within an endemic area.


Subject(s)
COVID-19 , Communicable Diseases , Malaria , Animals , Humans , Pandemics , COVID-19/epidemiology , Japan/epidemiology , Communicable Diseases/epidemiology , Malaria/epidemiology
2.
Respir Investig ; 61(4): 487-489, 2023 Jul.
Article in English | MEDLINE | ID: covidwho-2327189

ABSTRACT

Legionella pneumonia is a fatal disease caused by Legionella pneumophila, a bacterium belonging to the genus Legionella. The incidence of this disease has been increasing since 2005 and has continued to increase following the COVID-19 pandemic in Japan. Furthermore, Legionella pneumonia mortality rates have increased slightly since the pandemic due to some plausible reasons. The increased proportion of older patients with legionellosis might affect it because advanced age is a major risk factor for disease mortality. Additionally, physicians were focused on COVID-19 while examining febrile patients; therefore, they might have missed the early diagnosis of other respiratory infections, including Legionella pneumonia.


Subject(s)
COVID-19 , Legionella , Legionnaires' Disease , Humans , Japan/epidemiology , Pandemics , Legionnaires' Disease/epidemiology , Legionnaires' Disease/microbiology
3.
BMC Pulm Med ; 23(1): 111, 2023 Apr 06.
Article in English | MEDLINE | ID: covidwho-2300637

ABSTRACT

BACKGROUND: Eosinophilic airway inflammation caused by respiratory virus infection has been demonstrated in basic research; however, clinical investigations are lacking. To clarify the extent to which respiratory virus infection induces airway eosinophilic inflammation, we reviewed the results of bronchoalveolar lavage (BAL) and respiratory virus testing performed at our hospital. METHODS: Among the BAL procedures performed at the University of the Ryukyu Hospital from August 2012 to September 2016, we collected cases of acute respiratory disease in which multiplex polymerase chain reaction (PCR) was used to search for respiratory viruses. The effect of respiratory virus detection on BAL eosinophil fraction was analyzed using statistical analysis. A case study was conducted on respiratory virus detection, which showed an elevated BAL eosinophil fraction. RESULTS: A total of 95 cases were included in this study, of which 17 were PCR-positive. The most common respiratory virus detected was parainfluenza virus (eight cases). The PCR-positive group showed a higher BAL eosinophil fraction than the PCR-negative group (p = 0.030), and more cases had a BAL eosinophil fraction > 3% (p = 0.017). Multivariate analysis revealed that being PCR-positive was significantly associated with BAL eosinophil fraction > 1% and > 3%. There were nine PCR-positive cases with a BAL eosinophil fraction > 1%, of which two cases with parainfluenza virus infection had a marked elevation of BAL eosinophil fraction and were diagnosed with eosinophilic pneumonia. CONCLUSIONS: Cases of viral infection of the lower respiratory tract showed an elevated BAL eosinophil fraction. The increase in eosinophil fraction due to respiratory virus infection was generally mild, whereas some cases showed marked elevation and were diagnosed with eosinophilic pneumonia. Respiratory virus infection is not a rare cause of elevated BAL eosinophil fraction and should be listed as a differential disease in the practice of eosinophilic pneumonia.


Subject(s)
Pulmonary Eosinophilia , Respiratory Tract Infections , Virus Diseases , Viruses , Humans , Bronchoalveolar Lavage , Bronchoalveolar Lavage Fluid , Eosinophils , Inflammation , Pulmonary Eosinophilia/diagnosis , Respiratory Tract Infections/diagnosis , Retrospective Studies , Virus Diseases/diagnosis
4.
J Virol Methods ; 314: 114692, 2023 04.
Article in English | MEDLINE | ID: covidwho-2241972

ABSTRACT

Nucleic acid amplification test (NAAT) is the gold standard for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection. However, genetic mutations in the virus can affect the result. Cycle threshold (Ct) values of N genes and their association with mutations using SARS-CoV-2 positive specimens diagnosed by the Xpert Xpress SARS-CoV-2 were examined in this study. In total, 196 nasopharyngeal swab specimens were tested for SARS-CoV-2 infection using the Xpert Xpress SARS-CoV-2, and 34 were positive. WGS was performed for four outlier samples with increased ΔCt identified by Scatterplot analysis as well as seven control samples without increased ΔCt in the Xpert Xpress SARS-CoV-2. The presence of the G29179T mutation was identified as a cause of increased ΔCt. PCR using the Allplex™ SARS-CoV-2 Assay did not show a similar increase in ΔCt. Previous reports focusing on N-gene mutations and their effects on SARS-CoV-2 testing including the Xpert Xpress SARS-CoV-2 were also summarized. While a single mutation that impacts one target of a multiplex NAAT is not a true detection failure, mutation compromising NAAT target region can cause confusion of the results and render the assay susceptible to diagnostic failure.


Subject(s)
COVID-19 , SARS-CoV-2 , Humans , SARS-CoV-2/genetics , COVID-19/diagnosis , COVID-19 Testing , Clinical Laboratory Techniques/methods , Nasopharynx , Sensitivity and Specificity , Polymerase Chain Reaction , Nucleic Acid Amplification Techniques , Mutation
5.
JPRN; 06/01/2023; TrialID: JPRN-jRCTs071220085
Clinical Trial Register | ICTRP | ID: ictrp-JPRN-jRCTs071220085

ABSTRACT

Condition:

Mild and moderate I COVID-19 patients in out-of-hospital care

Intervention:

Colchicine or placebo for 14 days each

Primary outcome:

Number of fever-free days in 14 days

Criteria:

Inclusion criteria: (1) Patients with new-type coronavirus infection (COVID-19) with a fever of 37.5 degrees Celsius or higher on the day before assignment, confirmed by PCR or antigen, and who meet the following criteria
(1) Patients who fall under the Ministry of Health, Labour and Welfare (MHLW) Severity Classification*1 Mild or Moderate I (2,3,4 in the WHO ordinal scale for clinical improvement*2).
(2) One or more of the following symptoms are present
Runny or blocked nose, sore throat, shortness of breath, difficulty breathing, cough, lethargy, muscle or other aches, headache, chills
Feeling of fever, nausea, vomiting, diarrhea
(3) Patients whose disease onset and consent can be obtained within 5 days for hotel care patients and within 4 days for home care patients, and whose eligibility can be confirmed and allocation can be performed within the same period.
(4) Patients who are at least 18 years of age at the time consent is obtained
(5) In the case of women of childbearing potential or unprotected men*4, patients who agree to use adequate contraception from the time consent is obtained until 90 days after study drug administration
*1: Ministry of Health, Labour and Welfare Severity Classification
*2: WHO ordinal scale for clinical improvement
*3: Judgment is made based on medical history and medications. Obesity is judged based on self-reported weight and height.
*4: Sterilized men are defined as men who have been sterilized for at least one year after vasectomy and have documented absence of sperm at the time of ejaculation.
(6) Patients who can operate the following simple IT devices
The application is installed in the smart phone (not PC) and the data from the pulse oximeter is transmitted by Bluetooth function.
Can transmit automatically
Can use a smartphone for online medical services.
Receive and respond to web-based surveys, such as symptom surveys, via e-mail using a smartphone.
(7) Patients who have given a full explanation of their participation in this study, and who have given written consent of their own free will based on full understanding.

Exclusion criteria: (1) Patients with a history of hypersensitivity to colchicine products
(2) Patients who are receiving colchicine or have taken colchicine in the 30 days prior to the date of eligibility testing
(3) Patients with cirrhosis of the liver
(4) Patients with clinically documented biliary stasis, or patients whose medical history indicates a concern for biliary stasis.
(5) Patients with concerns about impaired renal function at the time of eligibility testing (estimated from medical history and medications taken)
(6) Patients with active malignancy
(7) Patients taking drugs listed as "concomitant medications" in the colchicine package insert as drugs that may interact with colchicine, and patients taking or wishing to take Ensitrelvir Fumaric Acid (XOCOVA)
(1) Drugs that inhibit hepatic metabolizing enzyme CYP3A4, etc.
a. Drugs that strongly inhibit
Preparations containing atazanavir, clarithromycin, indinavir, itraconazole, nelfinavir, ritonavir (including nilmatrelvir/ritonavir tablets: paclovid pack), saquinavir, darunavir, telithromycin, telaprevir, cobicistat
b. moderately inhibiting drugs*.
Amprenavir, aprepitant, erythromycin, fluconazole, fosamprenavir
*However, because the maximum blood concentration of colchicine is approximately 1.3 times higher and the AUC is approximately 2 times higher when it is administered with verapamil, it is recommended that the study drug be administered as colchicine at a dose of 1.0 mg on the first day and 0.5 mg every other day from the following day to ensure that the maximum blood concentration of colchicine is 1.0 mg on the first day and 0.5 mg every other day from the following day. It is estimated that the pharmacokinetics will be similar to those without verapamil. Diltiazem has a 1.3-fold highest blood concentration and 1.2-fold highest AUC, so no dose adjustment is necessary7).
Drugs that inhibit P-glycoprotein
Cyclosporine
(8) Patients taking amiodarone or quinidine
(9) Patients taking diltiazem or verapamil whose doses will be increased during the study period
(10) Pregnant or possibly pregnant patients, lactating patients, and patients who wish to become pregnant during the study period (for female subjects of childbearing potential, eligibility will be determined at the subject interview and a pregnancy test will be performed with the test drug provided by the study before the first dose of medication).
(11) Patients who are currently participating in another clinical trial/clinical study or have participated in another clinical trial/clinical study within 30 days prior to obtaining consent
(12) Other patients who are deemed inappropriate for this study by the investigators.

6.
PLoS One ; 17(1): e0261332, 2022.
Article in English | MEDLINE | ID: covidwho-1633231

ABSTRACT

Recent reports indicate that respiratory infectious diseases were suppressed during the novel coronavirus disease-2019 (COVID-19) pandemic. COVID-19 led to behavioral changes aimed to control droplet transmission or contact transmission. In this study, we examined the incidence of common infectious diseases in Japan during the COVID-19 pandemic. COVID-19 data were extracted from the national data based on the National Epidemiological Surveillance of Infectious Diseases (NESID). Common infectious diseases were selected from notifiable infectious diseases under the NESID. The epidemic activity of the diseases during 2015-2020 was evaluated based on the Infectious Disease Weekly Reports published by the National Institute of Infectious Diseases. Each disease was then categorized according to the route of transmission. Many Japanese people had adopted hygienic activities, such as wearing masks and hand washing, even before the COVID-19 pandemic. We examined the correlation between the time-series of disease counts of common infectious diseases and COVID-19 over time using cross-correlation analysis. The weekly number of cases of measles, rotavirus, and several infections transmitted by droplet spread, was negatively correlated with the weekly number of cases of COVID-19 for up to 20 weeks in the past. According to the difference-in-differences analysis, the activity of influenza and rubella was significantly lower starting from the second week in 2020 than that in 2015-2019. Only legionellosis was more frequent throughout the year than in 2015-2019. Lower activity was also observed in some contact transmitted, airborne-transmitted, and fecal-oral transmitted diseases. However, carbapenem-resistant Enterobacteriaceae, exanthema subitum, showed the same trend as that over the previous 5 years. In conclusion, our study shows that public health interventions for the COVID-19 pandemic may have effectively prevented the transmission of most droplet-transmitted diseases and those transmitted through other routes.


Subject(s)
COVID-19/pathology , Communicable Diseases/epidemiology , COVID-19/epidemiology , COVID-19/virology , Communicable Diseases/diagnosis , Databases, Factual , Health Behavior , Humans , Incidence , Influenza, Human/epidemiology , Japan/epidemiology , Masks , Pandemics , Rubella/epidemiology , SARS-CoV-2/isolation & purification
7.
Intern Med ; 61(1): 111-114, 2022 Jan 01.
Article in English | MEDLINE | ID: covidwho-1606787

ABSTRACT

We herein report four patients with community-acquired respiratory virus (CRV) infection. Although they had no history of contact with any individual with coronavirus disease 2019 (COVID-19), they were suspected of having COVID-19 based on findings of high-resolution computed tomography (CT) of the lungs. Among the four patients, two were infected with rhinovirus, one with metapneumovirus, and one with influenza A. Their chest CT findings were similar to those of COVID-19 patients reported in previous studies. Both CRV infection and COVID-19 can show various patterns on chest CT. CRV infection is thus indistinguishable from COVID-19 based on CT findings alone.


Subject(s)
COVID-19 , Influenza, Human , Humans , Lung , SARS-CoV-2 , Tomography, X-Ray Computed
9.
J Clin Virol ; 141: 104877, 2021 Aug.
Article in English | MEDLINE | ID: covidwho-1316526

ABSTRACT

BACKGROUND: . The emergence of SARS-CoV-2 variants has caused an unexpected rebound globally. The World Health Organization has listed three variants (B.1.1.7, B.1.351, and P.1) as variants of concern. To understand the epidemiology and thereby plan appropriate safety measures, differential identification of the variants is indeed critical. OBJECTIVES: . Although whole-genome sequencing is the gold standard for variant identification, it is time-consuming and relatively expensive. Therefore, a rapid, easy, and cost-effective platform targeting multiple regions of the genome is required. Here, we assessed the usefulness of the Novaplex™ SARS-CoV-2 Variants I Assay kit in identifying mutations in the variants. STUDY DESIGN: . We retrospectively examined 30 stored nasal swabs from COVID-19-positive patients tested between November 2020 and March 2021. RNA extracted from these swabs was subjected to the commercial kit and real-time reverse transcription-PCR was performed. To determine the genome sequences of SARS-CoV-2 in the collected samples and deduce the consensus sequences among the identified variants, genome sequencing libraries were prepared and mapped to the reference genome. RESULTS: . Four of the tested samples were determined as variants. Of them, two harbored both H69/V70 deletion and N501Y substitution, whereas two harbored E484K substitution alone. CONCLUSIONS: . The variant with E484K substitution alone ("R.1") has been now categorized as a variant of interest in Japan. Additionally, the kit-based assay was found to be feasible, convenient, and user-friendly in identifying the abovementioned mutations with a turnaround time of only 2 h.


Subject(s)
COVID-19 , SARS-CoV-2 , Humans , Mutation , Retrospective Studies , Spike Glycoprotein, Coronavirus/genetics
10.
Am J Trop Med Hyg ; 104(5): 1655-1658, 2021 Mar 18.
Article in English | MEDLINE | ID: covidwho-1302665

ABSTRACT

The COVID-19 pandemic has caused serious health and social concerns worldwide. Although the primary target of SARS-CoV-2 is the respiratory tract, SARS-CoV-2 infection also causes extrapulmonary symptoms. Previous articles have reported ischemic colitis in COVID-19 patients; however, information regarding its clinical manifestations and pathophysiology is limited. In this case report, we present two cases of ischemic enterocolitis in COVID-19 patients and review past case reports. Our literature review has shown that computed tomography rather than endoscopy was used for the diagnosis, and any region of the intestine was affected. Because the elevation of the D-dimer, which suggested a hypercoagulable state, was reported in most cases, we assumed that thrombosis at any level in the artery and vein was involved in the pathophysiology of COVID-19-associated enterocolitis. SARS-CoV-2-induced endotheliitis can cause both coarctation of the vessels and thrombosis; therefore, both patterns of ischemic colitis, occlusive and nonocclusive, may be involved in COVID-19-associated enterocolitis.


Subject(s)
COVID-19/complications , Colitis, Ischemic/etiology , Enterocolitis/etiology , SARS-CoV-2 , Aged , Female , Humans , Male , Middle Aged
11.
J Infect Chemother ; 27(7): 1112-1114, 2021 Jul.
Article in English | MEDLINE | ID: covidwho-1185071

ABSTRACT

Although rapid antigen tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is convenient, some articles have demonstrated their low sensitivity indicating false-negative results should always be considered. Here, we raise the issue of false-positive on rapid antigen tests for SARS-CoV-2 with the first case of acute HIV infection who repeatedly positive for the rapid antigen test. A 39-year-old man was admitted to our hospital complaining of high-grade fever, dry cough, general fatigue, and anorexia. The rapid antigen test performed on a nasopharyngeal swab sample was positive, therefore the patient was separated in an isolated room apart from the COVID-19 ward while awaiting the confirmatory RT-PCR result. However, the RT-PCR for SARS-CoV-2 performed on nasopharyngeal swabs was repeatedly negative (three times), while the antigen test was repeatedly positive (three times in total). This patient was eventually diagnosed with acute human immunodeficiency virus (HIV) infection based on a high titer of HIV-RNA and absence of plasma HIV-1/2 antibodies. Physicians should consider the possibility of false-positive results in addition to false-negative results when using a rapid antigen test for SARS-CoV-2, and keep in mind that nucleic acid amplification tests are needed to confirm the diagnosis.


Subject(s)
COVID-19 , HIV Infections , Adult , COVID-19 Serological Testing , HIV Infections/diagnosis , Humans , Immunologic Tests , Male , SARS-CoV-2 , Sensitivity and Specificity
12.
Am J Trop Med Hyg ; 104(3): 1018-1021, 2021 Jan 13.
Article in English | MEDLINE | ID: covidwho-1175680

ABSTRACT

Anticoagulation plays a major role in reducing the risk of systematic thrombosis in patients with severe COVID-19. Serious hemorrhagic complications, such as intracranial hemorrhage, have also been recognized. However, intra-abdominal hemorrhage is under-recognized because of its rare occurrence, despite high mortality. Here, we discuss two cases of spontaneous iliopsoas hematoma (IPH) likely caused by anticoagulants during the clinical course of COVID-19. We also explored published case reports to identify clinical characteristics of IPH in COVID-19 patients. The use of anticoagulants may increase the risk of lethal IPH among COVID-19 patients becsuse of scarce data on optimal dosage and adequate monitoring of anticoagulant effects. Rapid diagnosis and timely intervention are crucial to ensure good patient outcomes.


Subject(s)
Abscess/virology , COVID-19/complications , Hematoma/diagnosis , Hematoma/virology , Muscle, Skeletal/pathology , Abscess/classification , Abscess/diagnosis , Aged , Anticoagulants/adverse effects , Antiviral Agents/therapeutic use , Blood Coagulation , COVID-19/diagnostic imaging , Fatal Outcome , Hematoma/classification , Hematoma/drug therapy , Humans , Male , Middle Aged , Muscle, Skeletal/virology , Severity of Illness Index , Thigh/pathology , Tomography, X-Ray Computed , Treatment Outcome , COVID-19 Drug Treatment
13.
Case Rep Womens Health ; 30: e00309, 2021 Apr.
Article in English | MEDLINE | ID: covidwho-1155455

ABSTRACT

The case is presented of a 29-year-old primiparous woman who was COVID-19-positive at 34 weeks of gestation and who developed severe acute respiratory distress syndrome. After a four-day history of fever and mild dyspnea, she was referred to hospital. Ciclesonide, dexamethasone, heparin sodium, and sulbactam/ampicillin were initiated, followed by remdesivir and tocilizumab. On the fourth day after admission (at 34 weeks 5 days of gestation), respiratory failure required ventilator management. An emergency cesarean section was performed and a 2565-g male infant was delivered with an Apgar score of 8/8 and negative COVID-19 status. However, on the following day the patient's respiratory condition deteriorated and mechanical ventilation was initiated. Subsequently, her respiratory condition quickly improved and mechanical ventilation was terminated 4 days after intubation. She was discharged 12 days after cesarean delivery. Our case provides additional evidence that raises concerns regarding the unfavorable maternal consequences of COVID-19 infection during pregnancy.

14.
JPRN; 07/01/2021; TrialID: JPRN-jRCT2071200078
Clinical Trial Register | ICTRP | ID: ictrp-JPRN-jRCT2071200078

ABSTRACT

Condition:

Corona VIrus Disease 2019
COVID-19;COVID-19

Intervention:

1.5 mg of colchicine or placebo on day 1 and once daily oral administration of colchicine (0.5 mg) or placebo from day 2 to 28

Primary outcome:

Area under the curve (AUC) of amount of change of serum C-reactive protein from baseline at 1, 2, 4 weeks after initiating investigational drug

Criteria:

Inclusion criteria: (1) Patients with a definitive diagnosis of COVID-19 and written informed consent.
(2) Patients with oxygen saturation of more than 94% at room air and having either or both of the following:
a. Pneumonia shadow on chest imaging
b. Having more than one risk factors of the followings:
Diabetes mellitus, Cardiovascular disease (coronary disease, stroke, peripheral arterial disease, heart failure), Chronic obstructive pulmonary disease, chronic kidney disease (30 <= eGFR < 60), Obesity (BMI >= 30), Elderly (age >= 65 )
(3) Patients hospitalized within 5 days after the onset of symptoms and with the ability of administrating the investigational drug by the second day of hospitalization
(4) Adult patients aged more than 20 at informed consent
(5) Patients or partners of patients agreed to prevent pregnancy for 90 days from the day of initiating investigational drug
(6) Patients being able to understand and willing to sign an IRB approved written informed consent document

Exclusion criteria: (1)Asymptomatic patients
(2)Patients previously diagnosed COVID-19 in the past
(3)Known allergy or intolerance to colchicine
(4)Patients taking colchicine withing the past 30 days of consent date
(5)Patients taking biological drug withing the past 30 days of consent date
(6)Patients taking oral or intravenous corticosteroids withing the past 30 days of informed consent date
(7)Liver cirrhosis
(8)Clinical cholestasis
(9)Renal failure (eGFR < 30)
(10)Active or previous history of malignant disease
(11)Patients taking medicines as listed below:
a.Medicines strongly inhibiting CYP3A4
Atazanavir, Clarithromycin, Indinavir, Itraconazole, Nelfinavir, Ritonavir, Saquinavir, Darunavir, Telithromycin, Telaprevir, drugs containing kobishistat
b.Medicines moderately inhibiting CYP3A4
Amprenavir, Aprepitant, Diltiazem, Erythromycin, Fluconazole, Fosamprenavir, Verapamil
c.Medicines inhibiting P glycoprotein
Cyclosporine
(12)Patients taking Amiodarone or Quinidine
(13)Pregnant or possibly pregnant patients, patients with breastfeeding, patients willing to be pregnant
(14)Patients registered in other clinical trials/studies at informed consent date or in the past 30 days of informed consent date
(15)Patients being considered as inappropriate by attending physicians

15.
Respir Investig ; 59(1): 149-152, 2021 Jan.
Article in English | MEDLINE | ID: covidwho-947392

ABSTRACT

Since the Okinawan islands are located in the southernmost part of Japan, where the climate is subtropical, several episodes of influenza epidemics occur during the summer season. More recently, we have demonstrated that summer influenza epidemics occur every year. After the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in January 2020, measures to avoid disease transmission have been widely promoted in Japan, such as the use of masks, handwashing, remote work, and cancellation of large events. These measures might also have reduced the spread of other infectious diseases, such as the seasonal influenza. Based on this background, we evaluated weekly influenza activity in the 2019/2020 season. After the SARS-CoV-2 pandemic, the summer influenza in the Okinawa prefecture disappeared in 2020. The reasons for the disappearance of summer influenza in Okinawa are discussed herein.


Subject(s)
COVID-19/epidemiology , COVID-19/prevention & control , Disease Outbreaks/prevention & control , Influenza, Human/epidemiology , Pandemics , SARS-CoV-2 , Seasons , COVID-19/virology , Hand Disinfection , Humans , Influenza A Virus, H1N1 Subtype , Influenza, Human/prevention & control , Influenza, Human/virology , Japan/epidemiology , Personal Protective Equipment , Teleworking , Time Factors
17.
Intern Med ; 59(22): 2945-2949, 2020 Nov 15.
Article in English | MEDLINE | ID: covidwho-789033

ABSTRACT

Treatment with tocilizumab (TCZ) to block interleukin-6 (IL-6) signalling is predicted to mitigate cytokine release syndrome (CRS) caused by coronavirus disease 2019 (COVID-19). However, the adverse effects of TCZ on patients with COVID-19 remain unclear. We herein report a patient with COVID-19 treated with TCZ who developed acute hypertriglyceridaemia. Despite favipiravir treatment, acute respiratory distress syndrome developed in a 45-year-old patient with COVID-19; thus, TCZ was initiated. The triglyceride levels greatly increased after TCZ administration. Physicians should consider the negative impact of TCZ on the lipid profile in patients with COVID-19, although COVID-19-induced CRS itself may be an aggravating factor.


Subject(s)
Antibodies, Monoclonal, Humanized/adverse effects , Betacoronavirus , Coronavirus Infections/drug therapy , Hypertriglyceridemia/chemically induced , Pneumonia, Viral/drug therapy , Acute Disease , Antibodies, Monoclonal, Humanized/therapeutic use , COVID-19 , Coronavirus Infections/blood , Coronavirus Infections/epidemiology , Humans , Hypertriglyceridemia/blood , Interleukin-6/blood , Male , Middle Aged , Pandemics , Pneumonia, Viral/blood , Pneumonia, Viral/epidemiology , Retrospective Studies , SARS-CoV-2 , Triglycerides/blood
SELECTION OF CITATIONS
SEARCH DETAIL